[2] The safety profile of Orforglipron was consistent with existing GLP-1 therapies, with the most common adverse events being mild to moderate gastrointestinal symptoms such as diarrhea, nausea, dyspepsia, and constipation
Each rate is derived from the number of patients admitted for a PCH stay and who are 18 years or older on the date of admission, screened for an HRSN, and who screen positive for each of the five HRSNsfood insecurity, housing instability, transportation needs, utility difficulties, or interpersonal safetydivided by the number of patients 18 years or older on the date of admission screened for each of the five HRSNs
High-temperature processing significantly decreases organosulfur bioavailability, emphasizing the value of low-heat and minimal-water techniques
Donor-derived materials may differ in protein composition and glycosylation [63, 110]